Description
Padcev Medication
Padcev (Enfortumab Vedotin) is a Nectin-4-directed antibody and microtubule inhibitor conjugate used for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor, and a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting.
Dosage: The recommended dose of Padcev is 1.25 mg/kg (up to a maximum of 125 mg for patients ≥100 kg) should be administered as an intravenous infusion over 30 minutes on Days 1, 8 and 15 of a 28-day cycle until the disease is progressive or unacceptable toxicity occurs.
Side Effects: The most commonly reported enfortumab vedotin side effects include:
- Fatigue
- Peripheral neuropathy
- Decreased appetite
- Rash
- Alopecia
- Nausea
- Dysgeusia
- Diarrhea
- Dry eye
- Pruritus and dry skin
Warnings and Precautions:
- Closely monitor patients with enfortumab vedotin-ejfv 30 mg for blood glucose levels in patients with, or at risk for, diabetes mellitus or hyperglycemia.
- Monitor patients for symptoms of new or worsening peripheral neuropathy and consider dose interruption or dose reduction of enfortumab vedotin when peripheral neuropathy occurs.
- Padcev can cause fetal harm when administered to a pregnant woman. Females of reproductive potential are advised to use effective contraception during treatment with padcev 30 mg and for 2 months after the last dose.
- Male patients with female partners of reproductive potential are advised to use effective contraception while on treatment with enfortumab vedotin and for four months following the last dose.
- Due to the risk for serious adverse events in a breastfed child, lactating women are advised not to breastfeed while on treatment with padcev 20 mg and for at least 21 days after the last dose.
Reviews
There are no reviews yet.